Valuation: Avalo Therapeutics, Inc.

Market Cap 1.06B 918M 858M 784M 1.48B 101B 1.5B 10.06B 3.95B 50.59B 3.98B 3.89B 168B P/E 2026 *
-7.32x
P/E 2027 * -7.41x
Enterprise Value 636M 551M 515M 471M 887M 60.68B 901M 6.04B 2.37B 30.36B 2.39B 2.34B 101B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.3%
Yield 2026 *
0.06%
Yield 2027 * -
1 day-0.40%
1 week+4.96%
Current month+6.58%
1 month+2.86%
3 months-3.95%
6 months+35.54%
Current year+7.10%
1 week 17.87
Extreme 17.87
20
1 month 17.54
Extreme 17.54
20.01
Current year 12.51
Extreme 12.51
24.27
1 year 8.41
Extreme 8.41
24.27
3 years 3.39
Extreme 3.39
71.04
5 years 3.39
Extreme 3.39
9,331.13
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 13/02/2022
Director of Finance/CFO 42 13/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 07/08/2022
Director/Board Member 78 11/10/2020
Director/Board Member 55 27/03/2024
Date Insider Type Main position Quantity % Market Cap.
27/07/26 Fiscal year

Chief Technology Officer

3,000 0.0057%
30/06/26 Free

Director

1,080 0.0020%
30/06/26 Fiscal year

Chief Technology Officer

13,962 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%+4.96%+115.99%-36.64% 1.06B
+4.21%+25.56%+77.96%+104.49% 70.85B
-1.88%+3.46%+36.15%+65.65% 55.41B
-1.92%+34.32%+17.50%+491.37% 29.43B
-0.30%+13.64%+54.71%+6.07% 24.12B
+0.02%+1.16%-15.42%-13.57% 23.31B
-0.11%+6.23%+46.96%-21.73% 18.37B
+7.26%+14.16%+221.03%+393.89% 16.99B
0.00%+9.69%+31.01%+584.59% 16.1B
+0.23%-4.64%+42.74%+148.14% 13.12B
Average +0.75%+354.08%+62.86%+172.22% 26.88B
Weighted average by Cap. +1.00%+349.32%+55.08%+159.77%

Financials

2026 *2027 *
Net sales - -
Net income -108M -93.23M -87.15M -79.65M -150M -10.27B -152M -1.02B -401M -5.14B -404M -396M -17.11B -129M -112M -104M -95.43M -180M -12.31B -183M -1.22B -480M -6.16B -485M -474M -20.51B
Net Debt -424M -367M -343M -314M -591M -40.44B -600M -4.02B -1.58B -20.23B -1.59B -1.56B -67.38B -306M -265M -247M -226M -426M -29.14B -432M -2.9B -1.14B -14.58B -1.15B -1.12B -48.56B
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
Employees
33
Date Price Change Volume
11/08/26 US$19.45 -1.62% 31,317
10/08/26 US$19.77 +7.91% 977,859
07/08/26 US$18.32 -2.03% 730,255
06/08/26 US$18.70 -0.74% 596,213
05/08/26 US$18.84 +1.67% 734,514
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
19.77USD
Average target price
44.15USD
Spread / Average Target
+123.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVTX Stock